GERN vs NVS
GERN: Geron is a commercial-stage biopharma company focused on hematologic malignancies with its first-in-class telomerase inhibitor, RYTELO. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | GERN | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.22 | $143.11 | |
| Market cap | $784M | $227.4B | |
| P/E as of 2026-09-03 | n/a | 21.95 | |
| Net margin FY2023, SEC XBRL | -77690.7% | n/a | |
| Operating margin FY2023, SEC XBRL | -81832.9% | n/a | |
| ROE FY2025, SEC XBRL | -37.0% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | -14.6% | +12.6% | NVS higher |
| Debt / equity as of 2026-09-03 | 1.14 | 1.18 | GERN lower |
| Revenue growth (YoY) as of 2026-09-03 | +24.4% | +3.3% | GERN higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 1.11 | 0.23 | |
| 1-year return as of 2026-10-08 close | -11.6% | +8.2% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.